Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499302 | 1.00 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6846356 | 1.00 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL7743328 | 0.99 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Cns-5161 SCHEMBL29370312 | 0.89 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Cns-5161 SCHEMBL499356 | 0.89 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Cns-5161 SCHEMBL6420655 | 0.87 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2593943 | 0.85 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14126031 | 0.84 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6847040 | 0.84 | P2RX7 (0.37) | MAPTMEN1ALDH1A1HTTKMT2A | |
| SCHEMBL6717121 | 0.83 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | claimed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | claimed |
| EP-1888568-A4 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON INC (CA) | 2009-08-12 | — | — | EP | claimed |
| WO-2008116308-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-10-02 | — | — | WO | claimed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | claimed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | claimed |
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | claimed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GRIN2D 530/4885GRIN3B 218/4885GRIN1 136/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | GRIN2D 530/4885GRIN3B 218/4885GRIN1 136/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | GRIN2D 457/4885GRIN3B 172/4885GRIN1 304/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | GRIN2D 7/4885GRIN3B 6/4885GRIN1 4/4885 |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | OPRM1, NOS1, OPRK1 | GRIN2D 403/4885GRIN3B 83/4885GRIN1 167/4885 |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | GRIN2D 665/4885GRIN3B 166/4885GRIN1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.